| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
500126 Overview
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India.
Procter & Gamble Health Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5,382.70 |
| 52 Week High | ₹5,000.00 |
| 52 Week Low | ₹7,499.95 |
| Beta | 0.29 |
| 1 Month Change | 0.021% |
| 3 Month Change | -0.58% |
| 1 Year Change | 6.38% |
| 3 Year Change | 83.38% |
| 5 Year Change | 538.44% |
| Change since IPO | 130,865.94% |
Recent News & Updates
Shareholder Returns
| 500126 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.3% | -4.7% | -3.1% |
| 1Y | 6.4% | 18.5% | 61.0% |
Return vs Industry: 500126 underperformed the Indian Pharmaceuticals industry which returned 18.5% over the past year.
Return vs Market: 500126 underperformed the Indian Market which returned 61% over the past year.
Price Volatility
| 500126 volatility | |
|---|---|
| 500126 Beta | 0.29 |
| Industry Beta | 0.60 |
| Market Beta | 1 |
Stable Share Price: 500126 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: 500126's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 1,362 | Milind Thatte | https://www.pghealthindia.com |
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas brands.
Procter & Gamble Health Fundamentals Summary
| 500126 fundamental statistics | |
|---|---|
| Market Cap | ₹90.09b |
| Earnings (TTM) | ₹1.77b |
| Revenue (TTM) | ₹10.09b |
50.5x
P/E Ratio8.9x
P/S RatioIs 500126 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500126 income statement (TTM) | |
|---|---|
| Revenue | ₹10.09b |
| Cost of Revenue | ₹3.27b |
| Gross Profit | ₹6.82b |
| Expenses | ₹5.05b |
| Earnings | ₹1.77b |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 09, 2021
| Earnings per share (EPS) | 106.51 |
| Gross Margin | 67.62% |
| Net Profit Margin | 17.53% |
| Debt/Equity Ratio | 0% |
How did 500126 perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield38%
Payout RatioDoes 500126 pay a reliable dividends?
See 500126 dividend history and benchmarks| Procter & Gamble Health dividend dates | |
|---|---|
| Ex Dividend Date | Nov 02 2021 |
| Dividend Pay Date | Dec 08 2021 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 43 days |
Does 500126 pay a reliable dividends?
See 500126 dividend history and benchmarksValuation
Is Procter & Gamble Health undervalued compared to its fair value and its price relative to the market?
6.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 500126 (₹5382.7) is trading below our estimate of fair value (₹5726.46)
Significantly Below Fair Value: 500126 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 500126 is poor value based on its PE Ratio (50.5x) compared to the Indian Pharmaceuticals industry average (24.3x).
PE vs Market: 500126 is poor value based on its PE Ratio (50.5x) compared to the Indian market (21.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500126's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500126 is overvalued based on its PB Ratio (12.7x) compared to the IN Pharmaceuticals industry average (3x).
Future Growth
How is Procter & Gamble Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
16.9%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Procter & Gamble Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Procter & Gamble Health performed over the past 5 years?
23.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500126 has high quality earnings.
Growing Profit Margin: 500126's current net profit margins (17.5%) are lower than last year (18.7%).
Past Earnings Growth Analysis
Earnings Trend: 500126's earnings have grown significantly by 23.1% per year over the past 5 years.
Accelerating Growth: 500126's earnings growth over the past year (6.6%) is below its 5-year average (23.1% per year).
Earnings vs Industry: 500126 earnings growth over the past year (6.6%) underperformed the Pharmaceuticals industry 35.7%.
Return on Equity
High ROE: 500126's Return on Equity (25.1%) is considered high.
Financial Health
How is Procter & Gamble Health's financial position?
Financial Position Analysis
Short Term Liabilities: 500126's short term assets (₹7.3B) exceed its short term liabilities (₹2.4B).
Long Term Liabilities: 500126's short term assets (₹7.3B) exceed its long term liabilities (₹434.8M).
Debt to Equity History and Analysis
Debt Level: 500126 is debt free.
Reducing Debt: 500126 had no debt 5 years ago.
Debt Coverage: 500126 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 500126 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Procter & Gamble Health current dividend yield, its reliability and sustainability?
0.74%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 500126's dividend (0.74%) is higher than the bottom 25% of dividend payers in the Indian market (0.34%).
High Dividend: 500126's dividend (0.74%) is low compared to the top 25% of dividend payers in the Indian market (1.41%).
Stability and Growth of Payments
Stable Dividend: 500126's dividend payments have been volatile in the past 10 years.
Growing Dividend: 500126's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (37.6%), 500126's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Milind Thatte (52 yo)
3.5yrs
Tenure
₹32,345,000
Compensation
Mr. Milind Vasant Thatte, M.Pharm.Sci., M.B.A., has been Managing Director and Executive Director of Procter & Gamble Health Limited (formerly known as Merck Limited) since April 1, 2018. Mr. Thatte had a...
CEO Compensation Analysis
Compensation vs Market: Milind's total compensation ($USD431.44K) is about average for companies of similar size in the Indian market ($USD425.15K).
Compensation vs Earnings: Milind's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: 500126's management team is considered experienced (2.8 years average tenure).
Board Members
Experienced Board: 500126's board of directors are considered experienced (3.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Procter & Gamble Health Limited's employee growth, exchange listings and data sources
Key Information
- Name: Procter & Gamble Health Limited
- Ticker: 500126
- Exchange: BSE
- Founded: 1967
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹90.093b
- Shares outstanding: 16.60m
- Website: https://www.pghealthindia.com
Number of Employees
Location
- Procter & Gamble Health Limited
- Godrej One
- 8th Floor, Pirojshanagar
- Mumbai
- Maharashtra
- 400079
- India
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/25 12:01 |
| End of Day Share Price | 2021/10/25 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.